Literature DB >> 23640468

Interventional nuclear medicine.

V Ralph McCready, Sabina Dizdarevic, Mark Aplin.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23640468     DOI： 10.1007/s00259-013-2413-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  16 in total

1.  Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.

Authors:  Philip Hilgard; Monia Hamami; Amr El Fouly; André Scherag; Stefan Müller; Judith Ertle; Till Heusner; Vito R Cicinnati; Andreas Paul; Andreas Bockisch; Guido Gerken; Gerald Antoch
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

2.  Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.

Authors:  Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-03       Impact factor: 9.236

3.  Preliminary experience of infusional brachytherapy using colloidal 32P.

Authors:  S E Order; J A Siegel; R Principato; L S Zeiger; E Johnson; P Lang; R Lustig; C Kroprowski; P E Wallner
Journal:  Ann Acad Med Singapore       Date:  1996-05       Impact factor: 2.473

4.  Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.

Authors:  Stefan Kneifel; Dominik Cordier; Stephan Good; Mihai C S Ionescu; Anthony Ghaffari; Silvia Hofer; Martin Kretzschmar; Markus Tolnay; Christos Apostolidis; Beatrice Waser; Marlene Arnold; Jan Mueller-Brand; Helmut R Maecke; Jean Claude Reubi; Adrian Merlo
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

5.  Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas.

Authors:  J E Westlin; C Andersson-Forsman; U Garske; T Linné; M Aas; B Glimelius; P G Lindgren; S E Order; S Nilsson
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

6.  Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.

Authors:  D Cordier; F Forrer; F Bruchertseifer; A Morgenstern; C Apostolidis; S Good; J Müller-Brand; H Mäcke; J C Reubi; A Merlo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

Review 7.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

8.  Increased cancer incidence after radioiodine treatment for hyperthyroidism.

Authors:  Saara Metso; Anssi Auvinen; Heini Huhtala; Jorma Salmi; Heikki Oksala; Pia Jaatinen
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

9.  Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours.

Authors:  N P Rowell; V R McCready; D Tait; M A Flower; B Cronin; G E Adams; A Horwich
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

10.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Authors:  E Garin; L Lenoir; J Edeline; S Laffont; H Mesbah; P Porée; L Sulpice; K Boudjema; M Mesbah; A Guillygomarc'h; E Quehen; M Pracht; J L Raoul; B Clement; Y Rolland; E Boucher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236
View more
  1 in total

1.  Radioiodine - the success story of Nuclear Medicine : 75th Anniversary of the first use of Iodine-131 in humans.

Authors:  V Ralph McCready
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.